Clinical Edge Journal Scan

Utilization of AFP to predict HCC recurrence after liver transplantation in waitlisted patients


 

Key clinical point : Alpha-fetoprotein (AFP) levels during liver transplantation (LT) and their modulation while on the waitlist are predictors of hepatocellular carcinoma (HCC) recurrence after LT in patients meeting the Milan criteria.

Main finding: An AFP value >25.5 ng/mL (area under the receiver operating characteristic curve, 0.69) could strongly predict HCC recurrence after LT (subdistribution hazard ratio, 2.5; P = .01), which also showed a significant association with an increase in AFP levels by >20.8% while on the waitlist ( P = .034).

Study details: The data are derived from a retrospective single-center study that analyzed 207 patients with HCC fulfilling the Milan criteria who were put on the waitlist for LT and had AFP levels > 400 ng/mL at transplant.

Disclosures: Financial support for the study was provided by the association Friends of transplantation. The authors reported no conflict of interests.

Source: Magro B et al. Cancers. 2021 Nov 27. doi: 10.3390/cancers13235976 .

Recommended Reading

Atezolizumab plus bevacizumab benefits subset of HCC patients as first-line therapy
Federal Practitioner
Reduction hepatectomy plus multidisciplinary therapy improves HCC outcomes
Federal Practitioner
Transarterial chemoembolization plus percutaneous microwave ablation optimizes outcomes for unresectable HCC
Federal Practitioner
Lenvatinib tops sorafenib for progression-free survival in HCC
Federal Practitioner
Clinical Edge Journal Scan Commentary: HCC December 2021
Federal Practitioner
No survival benefits with first-line nivolumab vs sorafenib in advanced HCC
Federal Practitioner
Atezolizumab + bevacizumab shows long-term benefits over sorafenib for unresectable HCC
Federal Practitioner
HAIC-FO outperforms sorafenib against advanced HCC in phase 3
Federal Practitioner
Radiologic response to TACE-RT as a prognostic factor in advanced HCC with macroscopic vascular invasion
Federal Practitioner
Whole blood viscosity as a biomarker for distant metastasis and survival in HCC
Federal Practitioner